Seattle Genetics Inc. (SGEN)

SGEN (NASDAQ:Drugs)
$38.57
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | SGEN Avg Daily Volume: 1,181,600
Last Update: 04/16/14 - 4:00 PM EDT
Volume: 0
YTD Performance: -3.31%
Open: $0.00
Previous Close: $38.57
52 Week Range: $28.15 - $55.99
Oustanding Shares: 122,982,860
Market Cap: 4,557,509,692
6-Month Chart
TheStreet Ratings Grade for SGEN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 3 3 3 3
Moderate Buy 0 0 0 0
Hold 3 3 5 5
Moderate Sell 1 1 0 0
Strong Sell 2 2 2 2
Mean Rec. 2.89 2.89 2.80 2.80
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -104.80
Price Earnings Comparisons:
SGEN Sector Avg. S&P 500
-104.80 0.00 28.65
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-16.91% 5.47% 146.77%
GROWTH 12 Mo 3 Yr CAGR
Revenue 27.70 1.51 0.35
Net Income 0.00 -0.06 0.00
EPS 0.00 -0.23 0.00
Earnings for SGEN:
EBITDA -0.05B
Revenue 0.27B
Average Earnings Estimates
Qtr (03/14) Qtr (06/14) FY (12/14) FY (12/15)
Average Estimate $-0.20 $-0.23 $-0.98 $-0.67
Number of Analysts 9 8 10 8
High Estimate $-0.11 $-0.20 $-0.85 $-0.39
Low Estimate $-0.24 $-0.25 $-1.07 $-0.94
Prior Year $-0.14 $-0.06 $-0.51 $-0.98
Growth Rate (Year over Year) -39.68% -287.50% -91.96% 31.31%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Mar 29, 2014 | 8:00 AM EDT

TheStreet's Jim Cramer says newer pharmaceutical companies, like Celgene (CELG), Isis Pharmaceuticals (ISIS) and Seattle Genetics (SGEN), should be bought on any weakness because they have the potential to perform extremely well and may be better buys than Pfizer, Merck, Bristol-Myers and Eli Lilly.

By

Jim Cramer

 | Mar 23, 2014 | 6:00 AM EDT

For these kinds of growth stocks, you have no choice but to wait.

By

Jim Cramer

 | Mar 22, 2014 | 6:00 AM EDT

Here are some specific stocks working as parables right now.

By

Jim Cramer

 | Mar 19, 2014 | 8:04 AM EDT

It's sardonic, corroded commentary designed to keep your pole in the boat.

By

Jim Cramer

 | Mar 17, 2014 | 7:25 AM EDT

The public market is currently divorced from the dazzling IPOs -- and that's always a bad sign.

By

Doug Kass

 | May 8, 2013 | 10:18 AM EDT
Here is my compilation of last night's profit reports.

bearishSeattle Genetics downgraded at Needham

Feb 13, 2013 | 7:23 AM EST

SGEN was downgraded from Buy to Hold, Needham said. Adcetris sales are lagging expectations. 

 

bullishSeattle Genetics rated new Outperform at Credit Suisse

Nov 13, 2012 | 7:17 AM EST

SGEN was initiated with an Outperform rating, Credit Suisse said. $28 price target. Company is a market leader and can continue to grow. 

bearishSeattle Genetics downgraded at Cantor

Nov 8, 2012 | 7:02 AM EST

SGEN was downgraded from Hold to Sell, Cantor FItzgerald said. $20 price target. Adcetris is growing slower than expected. 

 

bearishSeattle Genetics downgraded at Oppenheimer

Sep 7, 2012 | 9:08 AM EDT

Shares of SGEN downgraded to Perform from Outperform, Oppenheimer said. $27 price target. Valuation call.

Market posts the third day of solid gains in a row. Will see if we can make it four a row...
With the averages now flying upwards, and everyone scrambling to buy, it is startling to r...
Inability of Bank of America (BAC) to claw its way above 16.30-.40 resistance will increas...
The Fed works for the government. The Federal government owes over $16 trillion. The Fed w...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.